Drug intelligence / Profile preview

Ido-C

Development stage: Unknown
Lead developer: Circius Pharma
Modality: Small Molecules
Administration: Oral

Overview

Ido-C is an over-the-counter (OTC) vitamin C supplement developed and marketed by Circius Pharma. It is formulated as orange-flavored chewable tablets, each containing 0.5 g of vitamin C provided as a combination of ascorbic acid (200 mg) and sodium ascorbate (338 mg). The supplement is indicated for the treatment and prevention of vitamin C deficiency, which can occur due to factors such as impaired intestinal absorption. Vitamin C serves as a critical antioxidant, protecting cells by trapping free radicals, and is essential for metabolic functions and the enhancement of iron absorption from food. Circius Pharma, a Swedish pharmaceutical company, acquired the product following its divestment from ABIGO Medical's pharmaceutical division in 2021.

Brand names: Ido-C
Other names: vitamin Cascorbic acidsodium ascorbate

Beyond the preview

Go deeper on Ido-C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ido-C.

Explore the full profile